Program - Society of Toxicology

Society of Toxicology 2011
Program Description (Continued)
Abstract #
Wednesday Afternoon, March 9
1:30 PM to 4:15 PM
Room 144
Emerging Global Public Health Issues
Workshop Session: Advancing Predictive Ecotoxicology
Testing and Environmental Risk Assessment in the 21st
Century
Chairperson(s): Michelle Embry, ILSI Health and Environmental
Sciences Institute, Washington, D.C., and David Volz, University of South
Carolina, Columbia, SC.
Sponsor:
Risk Assessment Specialty Section
Endorsed by:
Hispanic Organization for Toxicologists Special Interest Group
Molecular Biology Specialty Section
Following the publication of the National Research Council (NRC) Report
on Toxicity Testing in the 21st Century: A Vision and a Strategy increased
attention has been given to the development and use of new technologies
and methods for toxicity testing. It is hoped that these new approaches will
aid in the design of a routine testing strategy that will provide data that are
applicable to the broadest possible range of chemicals, endpoints, and lifestages,
while also providing greater detail concerning mode of action and
dose/concentration-response, and reducing the overall costs, animal use, and
time spent on testing. This Tox21 vision has impacted testing approaches
for not only human health, but also ecological risk assessment. Therefore it
is important to address these current initiatives aimed at advancing regulatory
ecotoxity testing strategies. Novel approaches that could be integrated
into an intelligent, tiered ecotoxicity testing strategy are under development.
Additionally, concepts for utilizing chemical mode of action and/or adverse
outcome pathways as a basis for developing 21st century test methods and
associated predictive tools, initially developed as part of a SETAC Pellston
workshop, have been expanded on several fronts. Advances in the application
of QSAR and modeling approaches, cell-based assays, and ‘omics
methodologies as well as recent OECD efforts to develop a fish testing
framework will be highlighted. Our focus will be to discuss approaches
to coordinate the development of new human health and environmental
toxicity testing strategies, share key lessons and advances and create effective
partnerships between human health and ecotoxicology communities.
#2462 1:30 ADVANCING PREDICTIVE
ECOTOXICOLOGY TESTING AND
ENVIRONMENTAL RISK ASSESSMENT IN
THE 21 ST CENTURY. ​M. Embry 1 and D. Volz 2 .
1
ILSI HESI, Washington, D.C. and 2 University of
South Carolina, Columbia, SC.
1:30 INTRODUCTION. ​Michelle Embry
#2463 1:35 ADVERSE OUTCOME PATHWAYS AND
SYSTEMS BIOLOGY AS CONCEPTUAL
APPROACHES TO SUPPORT
DEVELOPMENT OF 21 ST CENTURY TEST
METHODS AND EXTRAPOLATION TOOLS. ​
D. L. Villeneuve 1 , M. R. Embry 2 and D. C. Volz 3 .
1
U.S. EPA Mid-Continent Ecology Division, Duluth,
MN, 2 ILSI Health and Environmental Sciences
Institute, Washington, D.C. and 3 Department of
Environmental Health Sciences, University of South
Carolina, Columbia, SC.
#2464 2:07 ADVANCES AND OUTLOOKS FOR QSARS
IN ECOTOXICOLOGY. ​S. A. Villalobos 1 , S. E.
Belanger 2 and P. Ranslow 3 . 1 Nalco, Naperville, IL,
2
Procter & Gamble, Cincinnati, OH and 3 Consortium
for Environmental Risk Management, Hallowell,
ME.
Abstract #
#2465 2:39 FISH EMBRYO AND CELL LINE ASSAYS
AS POTENTIAL ALTERNATIVES FOR
FISH TOXICITY TESTS. ​K. Schirmer 1 , K.
Tanneberger 1 , M. Knöbel 1,3 , N. Kramer 2 , J. Hermens 2 ,
S. Scholz 3 , N. Bols 4 , L. Lee 5 and C. Hafner 6 . 1 Eawag,
Swiss Federal Institute of Aquatic Science and
Technology, Dübendorf, Switzerland, 2 Institute of
Risk Assessment Sciences, University of Utrecht,
Utrecht, Netherlands, 3 UFZ, Helholtz Centre
for Environmental Research, Leipzig, Germany,
4
University of Waterloo, Waterloo, ON, Canada,
5
Wilfrid Laurier University, Waterloo, ON, Canada
and 6 Hydrotox GmbH, Freiburg, Germany. Sponsor:
M. Embry.
#2466 3:11 CRITICAL EVALUATION OF ANIMAL
ALTERNATIVE TESTS FOR THE
IDENTIFICATION OF ENDOCRINE ACTIVE
SUBSTANCES. ​F. Busquet 1 , S. Belanger 2 , R.
Davi 3 , B. Demeneix 4 , J. Denny 5 , M. Embry 6 , M.
Léonard 7 , M. McMaster 8 , L. Ortego 9 , P. Renner 10 , D.
Villeneuve 5 and S. Scholz 10 . 1 JRC, IHCP, ECVAM,
European Commission, Ispra, Italy, 2 Procter &
Gamble, Cincinnati, OH, 3 ExxonMobil, Annandale,
NJ, 4 Muséum National d’Histoire Naturelle, CNRS,
Paris, France, 5 U.S. EPA, Duluth, MN, 6 ILSI HESI,
Washington, D.C., 7 L’Oréal Recherche Avancée,
Aulnay sous Bois, France, 8 Environment Canada,
Burlington, ON, Canada, 9 Bayer CropScience,
Research Triangle Park, NC and 10 UFZ, Leipzig,
Germany.
#2467 3:43 THE OECD FISH TESTING FRAMEWORK
PROJECT. ​L. Touart 1 , G. Ankley 2 , M. Embry 3 ,
A. Gourmelon 4 , T. Iguchi 5 , G. Maack 6 , P.
Matthiessen 7 , J. Wheeler 8 and C. Willett 9 . 1 OCSPP/
Office of Science Coordination and Policy, U.S.
EPA, Washington, D.C., 2 Office of Research and
Development, NHEERL, Mid-Continent Ecology
Division, U.S. EPA, Duluth, MN, 3 ILSI Health and
Environmental Sciences Institute, Washington,
D.C., 4 Organisation for Economic Cooperation and
Development (OECD), Paris, France, 5 National
Institute for Basic Biology (NIBB), Okazaki, Japan,
6
Umweltbundesamt (UBA), Dessau, Germany,
7
Consultant, Ulverston, United Kingdom, 8 Syngenta,
Bracknell, United Kingdom and 9 PETA, Norfolk,
VA.
Wednesday Afternoon, March 9
1:30 PM to 4:15 PM
Room 204
Workshop Session: De-Risking the Potential for
Cardiovascular Toxicity of Type-2 Diabetic Drugs: Preclinical
and Clinical Strategies
Chairperson(s): Alan Bass, Merck & Co., Kenilworth, NJ, and Peter
Hoffmann, Novartis, East Hanover, NJ.
Sponsor:
Drug Discovery Toxicology Specialty Section
Endorsed by:
Cardiovascular Toxicology Specialty Section
Discovery of effective therapies for the treatment of Type 2 Diabetes (T2D)
remains an important and critical unmet medical need for society. As with
the development of most new pharmaceuticals, the risk of failure of a
compound to achieve marketing authorization remains high. As a result,
the pharmaceutical industry has placed a strong commitment in implementing
strategies that de-risk the chance of failure when a compound is
selected for development. This commitment is reflected in the increasing
Wednesday
Poster Sessions
Regional Interest Session
Roundtable Sessions
Symposium Sessions
Thematic Sessions
Workshop Sessions
333